Cassava Sciences Newsroom

Cassava Sciences Options Spot-On: On November 25th, 168.87K Contracts Were Traded, With 300.78K Open Interest

On November 25th ET, $Cassava Sciences(SAVA.US)$ had active options trading, with a total trading volume of 168.87K options for the day, of which put options accounted for 34.72% of the total

Futu News05:30

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga05:05

Cassava Sciences Plummets Over 80% on Alzheimer's Trial Fail

Yahoo Finance04:57

Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October

Benzinga01:35

Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro

Breakings00:34

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Benzinga00:07

Trending Stocks Today | Quantum Shoots up 152.57%

November 25th - US stocks trending in regular trading hours.Gainers: $Quantum(QMCO.US)$ shoots up 152.57% to $23.06 with a turnover of $286.03 million. $QMMM Holdings(QMMM.US)$ surges 50.68% to $1.13

Futu NewsNov 25 23:40

Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings

BenzingaNov 25 22:47

U.S. stocks react | Simufilam's phase 3 Alzheimer's trial did not meet its endpoints, leading to a more than 84% plunge in cassava sciences (SAVA.US).

As of the time of publication, the stock has fallen by over 84%, reporting $4.06.

Zhitong FinanceNov 25 22:35

JonesTrading Maintains Cassava Sciences(SAVA.US) With Hold Rating

Futu NewsNov 25 22:32 · Ratings

JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)

TipRanksNov 25 22:15 · Ratings

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT NewswiresNov 25 22:09

Sector Update: Health Care

MT NewswiresNov 25 21:52

Cassava Sciences' Stock Craters After Alzheimer's Disease Trial Fails to Meet Its Goals

MarketWatchNov 25 21:50

Cassava Sciences' Alzheimer's Treatment Didn't Meet Endpoints in Study; Shares Dive -- Update

WSJNov 25 21:26

Express News | Cassava Sciences Shares Resume Trading Premarket, Last Down About 85% at $3.94 After Co's Alzheimer's Drug Failed in a Late-Stage Study

BreakingsNov 25 21:25

Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.

BenzingaNov 25 21:08

Cassava Sciences to Resume Trading at 8 A.m.

InvestingNov 25 20:58

Cassava Sciences Halts Alzheimer's Drug Trials After Phase 3 Results

BenzingaNov 25 20:31

Express News | Cassava Sciences Inc: Also Be Discontinuing Open Label Extension Study

BreakingsNov 25 20:30